Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.86 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 5/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74134 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL5162813 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL2457504 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL24215404 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL3787478 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL24754372 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL8394712 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL74855 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL76253 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 | |
| SCHEMBL74796 | 0.92 | DNM1 (1.00) | DNM1CASP2FAAHNAAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3245200-B1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-10 | — | — | EP | disclosed |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| WO-2016113168-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL)BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8287910-B2 | Polymeric micelles for polynucleotide encapsulation | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8101595-B2 | Antiviral indoles | Istituto di Ricerche di Biologia Molecolare P. Angletti SpA (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7767660-B2 | Antiviral indoles | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-08-03 | — | — | US | disclosed |
| US-20100076046-A1 | Antiviral Indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-03-25 | — | — | US | disclosed |
| US-7666880-B2 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2010-02-23 | — | — | US | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20080214522-A1 | Antiviral indoles | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-09-04 | — | — | US | disclosed |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076046-A1 | Antiviral Indoles | IDO1, ZC3HAV1, IFNAR1 | DNM1 2259/4885CASP2 3621/4885FAAH 2296/4885 |
| US-20080214522-A1 | Antiviral indoles | IDO1, ZC3HAV1, YBX1 | DNM1 2500/4885CASP2 3667/4885FAAH 2349/4885 |
| US-20180002314-A1 | 2-(PYRAZIN-2-YLCARBONYLAMINOMETHYL) BENZIMIDAZOLIUM COMPOUNDS AS EPITHELIAL SODIUM CHANNEL INHIBITORS | SCNN1A, TRPV1, SCNN1B | DNM1 3858/4885CASP2 1978/4885FAAH 4396/4885 |
| US-20100278927-A1 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION | NCL, POLN, CHMP4B | DNM1 1864/4885CASP2 4375/4885FAAH 4073/4885 |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | HDAC1, HDAC5, HDAC11 | DNM1 1651/4885CASP2 935/4885FAAH 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.